As part of ASAM’s “Advancing Access to Addiction Medications” project, the Treatment Research Institute was contracted to create “Medicaid Coverage of Medications for the Treatment of Opioid Use Disorder” state fact sheets. These two-page fact sheets summarize state Medicaid coverage of addiction treatment, both medication and counseling, and serve as an update to the June 2013 Patient Advocacy Task Force survey and research report on insurance coverage of addiction medications. In order to gather the most current nationwide coverage information, each state and the District of Columbia was surveyed to see if their Medicaid program covered methadone, Suboxone, buprenorphine/naloxone tablets (Zubsolv and generic), buprenorphine tablets, and injectable naltrexone (Vivitrol) under Fee-For-Service (FFS) or Managed Care (MC) plans.
The state fact sheets are currently available on the ASAM website, along with an interactive map of the United States. The purpose of this project is to improve access to addiction treatment by increasing knowledge and understanding of Medicaid coverage currently available and encouraging states to improve their program’s coverage of addiction treatment.
Source: American Society of Addiction Medicine – August 15, 2014